ADC - Ürgeová A., Javorský M., Klimčáková L., Židzik J., Šalagovič J., Hubáček J., Doubravová P., Gotthardová I., Kvapil M., Pelikánová T., Tkáč I., Yaluri A.: Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors. Pharmacogenomics - 2020 - 21, pp. 317-323, IF 2.533, Q3, Cited: 6x

ADC - Dujic T., Zhou K., Yee S., van Leeuwen N., de Keyser C., Javorský M., Goswami S., Zaharenko L., Hougaard M., Out M., Tavendale R., Kubo M., Hedderson M., van der Heijden A., Klimčáková L., Pirags V., Kooy A., Brosen K., Klovins J., Semiz S., Tkáč I., Stricker B. H., Palmer C., M't Hart L., Giacomini K. M., Pearson E. R.: Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A MetGen Meta-Analysis. Clinical Pharmacology & Therapeutics - 2017 - 101, pp. 763-772, IF 6.544, Q1, Cited: 37x

ADC - Gotthardová I., Javorský M., Klimčáková L., Kvapil M., Schroner Z., Kozárová M., Kozelová Z., Ürgeová A., Židzik J., Tkáč I.: KCNQ1 gene polymorphism is associated with glycaemic response to treatment with DPP-4 inhibitors. Diabetes Research and Clinical Practice - 2017 - 130, pp.142-147, IF 2.548, Q3, Cited: 11x

ADC - Zaharenko L., Kalnina I., Geldnere K., Konrade I., Solveiga G., Židzik J., Javorský M., Lejnieks A., Nikitina-Zake L., Fridmaonis D., Peculis R., Radovica I., Hartmane D., Pugovics O., Tkáč I., Klimčáková L., Pigags V., Klovins J.: Single nucleotide polymorphisms in the intergenic region between metformin transporter OCT2 and OCT3 coding genes are associated with short-term response to metformin monotherapy in type 2 diabetes mellitus patients. European Journal of Endocrinology - 2016 - 175, pp. 531-540, IF 4.101, Q1, Cited: 11x

ADC - Javorský M., Gotthardová I., Klimčáková L., Kvapil M., Klimčáková L., Schroner Z., Doubravová P., Gaľa I., Dravecká I., Tkáč I.: A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins. Diabetes Obesity & Metabolism - 2016 - 18, pp. 941-944, IF 6.715, Q1, Cited: 20x

VEGA 1/0183/20: Monitoring of genomic and proteomic markers of progression of the atherosclerosis in limb and carotid arteries in type 2 diabetes patients. Co-worker.

The project manager: prof. MUDr. Ivan Tkáč, PhD. Project duration: 2020-2023

Macrovascular diseases caused by atherosclerosis of the coronary, precerebral / cerebral and limb arteries are the most common cause of mortality in individuals with type 2 diabetes. The aim of the study is to evaluate the progression of morphological and functional parameters of carotid and limb atherosclerosis in relation to newly identified gene variants and proteomic markers in the period of 5 years after the first examination.

MZ 2019/29-UPJŠ-1: Monitoring the relationship of selected gene variants and proteomic markers in patients with mental disorders as a contribution to their personalized treatment. Co-worker.

The project manager: MUDr. Miriam Kozárová, PhD. Project duration: 2019-2022

The aim of the project is to identify at-risk populations, introduce prevention methods as well as innovative personalized treatment that would prevent the decline of cognitive functions and the development of dementia in elderly patients with diabetes mellitus type 2. The second part of the project is a pilot study focused on patients with depressive disorder, which aims to test innovative personalized pharmacotherapy in psychiatric practice, implemented on the basis of genetic profile and other selected markers.

APVV-16-0158 : Obesity, sleep apnea and obesity-hypoventilation syndrome: The impact of hypoxia on cardiovascular parameters in obesity-associated respiratory diseases and the possibilities of their treatment. Co-worker.

The project manager: doc. MUDr. Pavol Joppa, PhD. Project duration: 2017-2021

Obesity and related diseases are associated with a significantly increased risk of atherosclerosis, arterial hypertension, myocardial dysfunction and vascular dysfunction, as well as metabolic complications - metabolic syndrome and hepatic steatosis. Severe obesity leads to hemodynamic consequences resulting in changes in heart muscle morphology and left ventricular function with the development of heart failure. The coexistence of obesity and obstructive sleep apnea (OSA) or obesity-associated hypoventilation syndrome (OHS) may lead to the development of a syndrome known as obesity-associated cardiomyopathy. Given the high incidence of obesity, OSA, and OSH in the population it has become imperative to understand their pathogenetic mechanisms, therefore, the aim of the project was to identify appropriate treatments that would help decrease health and economic consequences of these diseases.

VEGA 1/0027/16: Monitoring of associations of selected gene variants with response to treatment with oral antidiabetics gliptins. Co-worker.

The project manager: prof. MUDr. Ivan Tkáč, PhD. Project duration: 2016-2019

The aim of the project was to identify gene variants that are related to the response to gliptin treatment in diabetic patients. In clinical practice, the knowledge gained can be applied in the future in "personalized medicine". Based on the identified gene profile, personalized medicine will allow the right choice of the most appropriate treatment, which will be beneficial for patients, but will also allow optimal allocation of financial resources to effective drugs without the need for therapeutic trials with unclear results.

VEGA 1/0724/15: Novel genetic mutations in the pathogenesis of dystonia: their importance, prevalence and manifestation. Co-worker.

The project manager: RNDr. Viera Habalová, PhD. Project duration: 2015-2017

Recent genetic research of dystonia has led to the discovery of new monogenic causes of this disease. Until recently, the group of dystonias with verified monogenic basis was limited to rare, often generalized forms of dystonia with an early age of onset.  The progress in genetics has enabled the identification of new genes (ANO3, CIZ1 and GNAL) causing the most common forms of dystonia: adult-onset focal or segmental dystonia. These mutations were described worldwide by only a few scientific groups, and the relationship of individual mutations to a particular phenotype of dystonia, their penetrance and therapeutic response was not clearly known. The aim of this project was to determine the prevalence of mutations of newly discovered genes ANO3, CIZ1 and GNAL in patients with focal and segmental dystonia and subsequent long-term monitoring of the examined population in order to specify the genotype-phenotype correlation, as well as monitoring of the therapeutic response in individual patients.